GenSight Biologics S.A.
GSGTF
$0.19
-$0.05-20.79%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 10.67% | 19.21% | 24.40% | 37.74% | 46.58% |
| Total Depreciation and Amortization | -53.74% | -63.73% | -68.48% | -60.05% | -51.41% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 273.98% | 1,837.65% | -41.81% | 86.10% | 71.75% |
| Change in Net Operating Assets | -9.83% | 212.58% | 376.20% | 79.01% | -64.36% |
| Cash from Operations | 24.84% | 38.37% | 48.84% | 48.54% | 47.52% |
| Capital Expenditure | -360.00% | 64.06% | 100.00% | 95.58% | 90.74% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1,020.00% | 59.08% | -161.52% | -109.58% | -91.76% |
| Cash from Investing | 1,061.96% | 76.64% | -171.47% | -110.64% | -91.85% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 56.68% | -14.00% | -307.16% | -123.14% | -54.56% |
| Issuance of Common Stock | -60.95% | -60.74% | -60.50% | 16.53% | 299.62% |
| Repurchase of Common Stock | -- | 96.62% | 95.87% | 85.45% | 72.73% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 516.90% | 21.65% | -170.04% | -138.36% | 311.36% |
| Cash from Financing | -28.94% | -67.69% | -92.02% | -59.53% | -14.65% |
| Foreign Exchange rate Adjustments | 101.64% | -20.64% | -537.62% | -414.26% | -346.46% |
| Miscellaneous Cash Flow Adjustments | -90.91% | -100.00% | 100.00% | 220.00% | -- |
| Net Change in Cash | -70.15% | -205.90% | -213.21% | -142.94% | 103.81% |